EDITAS MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.32 USD | +1.92% |
|
-3.10% | -47.48% |
| Sales 2024 * | 34.3M 46.88M | Sales 2025 * | 24.82M 33.93M | Capitalization | 437M 598M |
|---|---|---|---|---|---|
| Net income 2024 * | -206M -282M | Net income 2025 * | -242M -331M | EV / Sales 2024 * | 5.4 x |
| Net cash position 2024 * | 252M 345M | Net cash position 2025 * | 95M 130M | EV / Sales 2025 * | 13.8 x |
| P/E ratio 2024 * |
-2.17
x | P/E ratio 2025 * |
-2.08
x | Employees | 265 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Editas Medicine, Inc.
More recommendations
More press releases
| 1 day | +1.92% | ||
| 1 week | -3.10% | ||
| Current month | -28.30% | ||
| 1 month | -26.32% | ||
| 3 months | -27.02% | ||
| 6 months | -18.28% | ||
| Current year | -47.48% |
1 week
5.11
5.92
1 month
5.117.52
Current year
5.1111.58
1 year
5.1111.91
3 years
5.1173.03
5 years
5.1199.95
10 years
5.1199.95
| Managers | Title | Age | Since |
|---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 22-05-31 |
Erick Lucera
DFI | Director of Finance/CFO | 57 | 23-05-16 |
Linda Burkly
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Emma Reeve
CHM | Chairman | 63 | 21-09-02 |
David Scadden
BRD | Director/Board Member | 71 | 19-02-05 |
Akshay Vaishnaw
BRD | Director/Board Member | 61 | 16-07-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.83% | 2 M€ | -25.75% | ||
| 0.13% | 2 M€ | -.--% | ||
| 0.09% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.32 | +1.92% | 1,352,190 |
| 24-04-25 | 5.22 | -2.43% | 1,543,788 |
| 24-04-24 | 5.35 | -2.01% | 1,908,326 |
| 24-04-23 | 5.46 | -2.50% | 1,648,540 |
| 24-04-22 | 5.6 | +2.00% | 1,745,138 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
5.32
USD
Average target price
15.4
USD
Spread / Average Target
+189.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.48% | 437M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EDIT Stock
